Coronavirus information

Information on the coronavirus pandemic for our patients and visitors.

View coronavirus information

FOI 0814 2020/21 Lung and Melanoma Patient Treatment

Freedom of Information Request: 0814 2020/21

 I have a Freedom of Information request that I hope you’ll be able to help me with

Queen Elizabeth Hospital Birmingham:

  • In the past 3 months, how many metastatic melanoma patients were treated by your Trust?

 

Dabrafenib – 0

Dabrafenib + Trametinib – 0

Densoumab – 0

Encorafenib + Binimetinib – 1

Ipilimumab – 0

Ipilimumab + Nivolumab – 6

Nivolumab – 0

Pembrolizumab  – 2

Trametinib – 0

Vemurafenibb – 0

Vemurafenib + Cobimetinib – 0

Other active systemic anti-cancer therapy – 0

Palliative care only – 0

  • Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following:

 

Afatinib – 0

Atezolizumab monotherapy or combination – 0

Brigatinib – 0

Ceretinib – 0

Crizotinib – 0

Docetaxel monotherapy or combination – 0

Erlotinib – 0

Gefitinib – 0

Gemcitabine – 2

Nitendanib + docetaxel – 0

Nivolumab – 0

Osimertinib – 0

Paclitaxel – 1

Pembrolizumab monotherapy – 1

Pembrolizumab chemo in combination – 2

Pembrolizumab monotherapy – 0

Pemetrexed monotherapy or combination – 1

Ramucirumab – 0

Vinorelbine monotherapy or combination – 0

Other active systemic anti-cancer therapy – 0

Palliative care only – 2

  • Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC ) with the following products?

 

Afatinib – 0

Atezolizumab monotherapy or combination – 0

Brigatinib – 0

Ceretinib – 0

Crizotinib – 0

Docetaxel monotherapy or combination – 0

Erlotinib – 0

Gefitinib – 0

Gemcitabine – 0

Nitendanib + docetaxel – 0

Nivolumab – 0

Osimertinib – 0

Paclitaxel – 0

Pembrolizumab monotherapy – 1

Pembrolizumab chemo in combination – 1

Pembrolizumab monotherapy – 0

Pemetrexed monotherapy or combination – 1

Ramucirumab – 0

Vinorelbine mono or combination – 0

Other active systemic anti-cancer therapy – 0

Palliative care only – 0

 

Heartlands, Good Hope and Solihull Hospitals (HGS):

  • In the past 3 months, how many metastatic melanoma patients were treated by your Trust?

 

Not Applicable, Melanoma patients are not treated at HGS

Dabrafenib

Dabrafenib + Trametinib

Densoumab

Encorafenib + Binimetinib

Ipilimumab

Ipilimumab + Nivolumab

Nivolumab

Pembrolizumab 

Trametinib

Vemurafenib

Vemurafenib + Cobimetinib

Other active systemic anti-cancer therapy

Palliative care only

 

  • Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following:

 

*Please see below response

Afatinib

Atezolizumab monotherapy or combination

Brigatinib

Ceretinib

Crizotinib

Docetaxel monotherapy or combination

Erlotinib

Gefitinib

Gemcitabine

Nitendanib + docetaxel

Nivolumab

Osimertinib

Paclitaxel

Pembrolizumab monotherapy

Pembrolizumab chemo in combination

Pembrolizumab monotherapy

Pemetrexed monotherapy or combination

Ramucirumab

Vinorelbine monotherapy or combination

Other active systemic anti-cancer therapy

Palliative care only

  • Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC ) with the following products?

 

*Please see below response

Afatinib

Atezolizumab monotherapy or combination

Brigatinib

Ceretinib

Crizotinib

Docetaxel monotherapy or combination

Erlotinib

Gefitinib

Gemcitabine

Nitendanib + docetaxel

Nivolumab

Osimertinib

Paclitaxel

Pembrolizumab monotherapy

Pembrolizumab chemo in combination

Pembrolizumab monotherapy

Pemetrexed monotherapy or combination

Ramucirumab

Vinorelbine mono or combination

Other active systemic anti-cancer therapy

Palliative care only

 

*Please note for the above questions we are unable to determine from our Pharmacy systems if these patients have squamous or non-squamous histology, therefore we have provided the total number of metastatic NSCLC patients being treated at HGS.

Afatinib – 4

Atezolizumab monotherapy or combination – 7

Brigatinib – 0

Ceritinib – 2

Crizotinib – 0

Docetaxel monotherapy or combination – 5

Erlotinib – 0

Gefitinib – 5

Gemcitabine – 17

Nitendanib + docetaxel – 0

Nivolumab – 0

Osimertinib – 7

Paclitaxel – 1

Pembrolizumab monotherapy – 22

Pembrolizumab chemo in combination – 4

Pembrolizumab monotherapy – Duplicate – see answer above.

Pemetrexed monotherapy or combination – 15

Ramucirumab – 0

Vinorelbine monotherapy or combination – 4

Other active systemic anti-cancer therapy – 22

Palliative care only – Pharmacy system does not record to this detail

 

Thinking of going to Accident and Emergency but not sure if you need to? Try our handy symptom checker.

Try ask A&E

We're improving the accessibility of our websites. If you can't access any content or if you would like to request information in another format, please view our accessibility statement.